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ABSTRACT
Background. Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurode-
generative disease characterised by the accumulation of aggregated proteins, microglia
activation andmotor neuron loss. The mechanisms underlying neurodegeneration and
disease progression in ALS are unknown, but the ATP-gated P2X7 receptor channel is
implicated in this disease. Therefore, the current study aimed to examine P2X7 in the
context of neurodegeneration, and investigate whether the P2X7 antagonist, Brilliant
Blue G (BBG), could alter disease progression in a murine model of ALS.
Methods. Human SOD1G93A transgenic mice, which normally develop ALS, were
injected with BBG or saline, three times per week, from pre-onset of clinical disease
(62–64 days of age) until end-stage. During the course of treatment mice were assessed
for weight, clinical score and survival, and motor coordination, which was assessed by
rotarod performance. Various parameters from end-stagemice were assessed as follows.
Motor neuron loss and microgliosis were assessed by immunohistochemistry. Relative
amounts of lumbar spinal cord SOD1 and P2X7 were quantified by immunoblotting.
Serummonocyte chemoattractant protein-1 wasmeasured by ELISA. Splenic leukocyte
populations were assessed by flow cytometry. Relative expression of splenic and hepatic
P2X7 mRNA was measured by quantitative real-time PCR. Lumbar spinal cord SOD1
and P2X7 were also quantified by immunoblotting in untreated female SOD1G93A mice
during the course of disease.
Results. BBG treatment reduced body weight loss in SOD1G93A mice of combined sex,
but had no effect on clinical score, survival or motor coordination. BBG treatment
reduced body weight loss in female, but not male, SOD1G93A mice. BBG treatment
also prolonged survival in female, but not male, SOD1G93A mice, extending the mean
survival time by 4.3% in female mice compared to female mice treated with saline.
BBG treatment had no effect on clinical score or motor coordination in either sex. BBG
treatment had no major effect on any end-stage parameters. Total amounts of lumbar
spinal cord SOD1 and P2X7 in untreated female SOD1G93A mice did not change over
time.
Discussion. Collectively, this data suggests P2X7 may have a partial role in ALS pro-
gression in mice, but additional research is required to fully elucidate the contribution
of this receptor in this disease.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is themost common form of adult-onset motor neuron
disease, and is characterised by the degeneration and death of both upper and lower motor
neurons (Boillee, Vande Velde & Cleveland, 2006). This leads to progressive spasticity,
muscle weakness and muscle atrophy, culminating in paralysis and death, generally within
3–5 years from clinical onset (Al-Chalabi et al., 2012). While most cases of ALS are sporadic
(sporadic ALS, or sALS) and of unclear cause, the 5–10% of cases in which the disease is in-
herited (familial ALS, or fALS) can be linked to specific geneticmutations.Mutations in one
ormore of at least a dozen genes give rise to distinct disease neuropathological subtypes, each
of which is associated with the aggregation of a variety of proteins into inclusions with histo-
logically distinct structures. The inclusions in ALS can also be categorized on the basis of the
dominant protein involved, such as Cu, Zn superoxide dismutase 1 (SOD1), and the RNA-
binding proteins, TDP-43 and FUS, which result in inclusions with varied characteristics
(Farrawell et al., 2015). Protein aggregates associated with ALS pathology are thought to
drive progression of disease, possibly through a prion-like action (Grad et al., 2014) or by
chronically activating microglia (Roberts et al., 2013).
SOD1was the first gene inwhichmutationswere found to be associatedwithALS, and ac-
count for approximately 20%of familial cases (2%of all cases) (Rosen et al., 1993). To inves-
tigate mechanisms of disease and potential therapeutic strategies, several transgenic super-
oxide dismutase 1 (SOD1)ALSmousemodels have been generated (Turner & Talbot, 2008),
including the SOD1G93A mouse model (Gurney et al., 1994). SOD1G93A mice carry a high
copy number of a transgene encoding for the G93A variant of human SOD1, and develop
an ALS-like disease which is characterised by the loss of motor neurons leading to hind
limb weakness and paralysis (Gurney et al., 1994). These mice display similar pathological
hallmarks to those seen in the human disease (Cheroni et al., 2005;Hall, Oostveen & Gurney,
1998; Kawaguchi-Niida et al., 2013), and display a similar gender incidence and prevalence
of disease to human ALS (Cervetto et al., 2013;McCombe & Henderson, 2010; Veldink et al.,
2003).
Neuroinflammation is emerging as a central component of ALS progression (Henkel et
al., 2009). In the central nervous system (CNS), activation of the ATP-gated P2X7 receptor
channel is responsible for mediating a number of neuroinflammatory events, including
microglial activation and proliferation (Monif et al., 2009). P2X7 immunoreactivity is
increased in activated microglia of spinal cords from (post-mortem) humans with ALS and
advanced-stage transgenic SOD1G93A rats (Casanovas et al., 2008;Yiangou et al., 2006). Fur-
thermore, P2X7 is up-regulated in primary microglia from SOD1G93A mice (D’Ambrosi et
al., 2009). These cells produce increased amounts of pro-inflammatory factors and undergo
oxidative stress following ATP stimulation (Apolloni et al., 2013b; D’Ambrosi et al., 2009;
Parisi et al., 2013; Parisi et al., 2016). These exacerbated pro-inflammatory responses lead
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to the death of neuronal cell lines, and are abrogated by pharmacological blockade or gene
deletion of microglial P2X7. Similarly, ATP-induced activation of P2X7 causes neurotoxic
phenotypes in wild type (WT) microglia and WT or SOD1G93A astrocytes, leading to the
death of co-cultured neurons (Gandelman et al., 2010; Skaper et al., 2006).
Despite the deleterious effects reported for P2X7 in an ALS context in vitro, current in
vivo evidence suggests amore complex dual role for this receptor. In SOD1G93A mice lacking
the P2RX7 gene, females, but not males, had an extended lifespan compared to SOD1G93A
mice encoding P2X7 (Apolloni et al., 2013a). However, these double transgenic mice also
had anticipated onset, accelerated disease progression and increased astrocytosis,microglio-
sis and motor neuron loss compared to mice carrying the SOD1G93A transgene alone. This
suggests that constitutive deletion of P2X7 is detrimental in ALS, but that this receptor
may be neuroprotective during the early stages of the disease. Supporting this hypothesis,
administration of the P2X7 antagonist, Brilliant BlueG (BBG), beginning at late pre-onset of
clinical disease delayed disease onset, improved condition andmotor coordination, reduced
microgliosis and inflammatory markers and enhanced motor neuron survival (Apolloni et
al., 2014). Similarly, administration of BBG beginning at disease onset improved motor
coordination and slowed weight loss in male, but not female, SOD1G93A mice (Cervetto
et al., 2013). However, BBG inhibition of P2X7 did not correspond with an increase in
survival in either study (Apolloni et al., 2014; Cervetto et al., 2013).
To further investigate P2X7 in ALS progression, this study aimed to investigate whether
administration of BBG could alter disease progression in SOD1G93A mice, beginning at the
pre-onset of clinical disease. Body weight, ALS score and motor coordination were moni-
tored throughout. Furthermore, a number of pathological hallmarks of disease were anal-
ysed at end-stage, including motor neuron counts, microgliosis, lumbar P2X7 and SOD1
protein amounts and serummonocyte chemoattractant protein-1 (MCP-1) concentrations.
MATERIALS AND METHODS
Reagents and antibodies
BBG, ethidium bromide, ATP, paraformaldehyde (PFA), RNAlater and glycerol gelatin
were from Sigma-Aldrich (St. Louis, MO, USA). Sterile 0.9%NaCl was from Fresenius Kabi
(BadHomburg, Germany). Agarose was fromBioline (Alexandria, Australia). Ammonium-
chloride-potassium (ACK) lysing buffer, N-PERTM neuronal protein extraction reagent,
100 × HaltTM protease inhibitor single-use cocktail, normal horse serum (NHS),
DNase/RNase-free distilled water and SuperSignal West Pico Chemiluminescent Substrate
were from ThermoFisher Scientific (Waltham, MA, USA). Foetal bovine serum (FBS)
was from Lonza (Basel, Switzerland). Tissue-Tek R© optimal cutting temperature (OCT)
compound was from Sakura (Flemingweg, Netherlands) and 22 mm glass coverslips were
fromMenzel Glaser (Braunschweig, Germany). Diploma full-creammilk powder was from
Fonterra (Mount Waverley, Australia). Bovine serum albumin (BSA) and all other reagent
grade chemicals and salts were from Amresco (Solon, OH, USA). The antibodies used are
listed in Table 1.
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Table 1 Antibodies used to investigate the efficacy of the P2X7 antagonist Brilliant Blue G on ALS pro-
gression.
Antibody targeta Conjugatea Host species Companyb (catalogue
number)
Mouse CD45 FITC Rat BioLegend (103107)
IgG2b isotype control FITC Rat AbD (MCA1125FT)
Mouse CD8α PE Rat BioLegend (100707)
Mouse CD25 PE Rat BioLegend (101903)
Mouse/human CD11b PE Rat BioLegend (101207)
IgG2a isotype control PE Rat eBioscience (12-4321-80)
Mouse CD3ε PerCP/Cy5.5 Armenian hamster BioLegend (100327)
Mouse CD11c PerCP/Cy5.5 Armenian hamster BioLegend (117327)
IgG isotype control PerCP/Cy5.5 Armenian hamster BioLegend (400931)
Mouse CD19 APC Rat BioLegend (115511)
Mouse CD4 APC Rat BioLegend (100411)
Mouse Ly-6G APC Rat BioLegend (127613)
IgG2a isotype control APC Rat BioLegend (400511)
Rabbit IgG Alexa Fluor 647 Goat Abcam (ab150079)
Mouse IgG Alexa Fluor 488 Goat ThermoFisher (A11001)
Iba1 – Rabbit Wako (019–19741)
Neuron-specific β3 tubulin – Mouse Abcam (ab78078)
P2X7 (extracellular) – Rabbit Alomone Labs (APR-008)
Superoxide dismutase 1 – Sheep Abcam (ab8866)
IgG isotype control – Rabbit Abcam (ab171870)
IgG2a isotype control – Mouse ICL (RS-90G2a)
Rabbit IgG Peroxidase Goat Rockland (611-103-122)
Sheep IgG Peroxidase Donkey Merck Millipore (AB324P)
Notes.
aAPC, allophycocyanin; Cy5.5, cyanine5.5; FITC, fluorescein isothiocyanate; Iba1, ionised calcium binding adaptor molecule 1;
Ig, immunoglobulin; PE, phycoerythrin; PerCP, peridinin chlorophyll.
bAbcam, Cambridge, United Kingdom; AbD Serotec, Puchheim, Germany; Alomone Labs, Jerusalem, Israel; BioLegend, San
Diego, CA; eBioscience, San Diego, CA; ICL, Immunology Consults Laboratory, Portland, OR; Merck Millipore, Billerica, MA;
Rockland Immunochemicals, Gilbertsville, PA; ThermoFisher Scientific (Waltham, MA); Wako, Osaka, Japan.
Animals
Animal studies were performed with the approval (AE11/29 and AE12/09) of the Animal
Ethics Committee of the University of Wollongong (Wollongong, Australia). Mice
hemizygous for the human SOD1G93A transgene and back-crossed (>5 generations) onto a
C57BL/6J background (B6-Tg(SOD1-G93A)1GUr/j) were originally provided by Bradley
Turner (University of Melbourne, Melbourne, Australia). Mice were bred and maintained
at the Australian BioResources (ABR) Animal Facility (Moss Vale, Australia). At weaning,
transgenic SOD1mice were genotyped and relative SOD1 copy number assessed (Data S1).
At 45–57 days of age (d), transgenic SOD1mice with relatively similar SOD1 copy numbers
were transported to and housed at the University of Wollongong in a temperature-
controlled environment on a 12:12 h light-dark cycle, with light onset at 7:00 AM. Mice
were matched for SOD1 copy number, age and sex, and divided into two treatment groups
(Table 2). Mice were caged with paired littermates where possible, with 4–5 females or 3
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Table 2 Characteristics of mouse treatment groups at the beginning of treatment.
Female Male
Saline BBG Saline BBG
Number of mice (n) 12 13 9 8
Copy number (1Ct ) 6.2± 0.2 6.2± 0.1 6.3± 0.1 6.3± 0.1
Starting age (d) 63.3± 0.9 63.5± 0.8 63.4± 0.7 63.6± 0.7
Starting weight (g) 17.2± 0.8 17.4± 0.9 22± 1 21.4± 0.4
Starting ALS score 0± 0 0± 0 0± 0 0± 0
Notes.
No significant differences between groups for any parameter (SOD1 transgene copy number, age, weight or score) at the be-
ginning of treatment. Copy number is determined as the difference in the crossing points for the hSOD1 and mApoB curves
(1Ct ). Results shown as means± SD. BBG, Brilliant Blue G.
males per cage (unless fighting and required separation). Food and water was available ad
libitum. When mice became symptomatic (clinical score > 2) and unable to access water
or food, longer sippers were placed onto water bottles and food pellets placed directly onto
the cage floor.
To investigate lumbar SOD1 and P2X7 proteins over time, female SOD1G93A mice or
WT littermates lacking the SOD1 transgene at 30, 60, 90 and 120 d (3–5 per group) were
genotyped by the Garvan Institute of Medical Research (Darlinghurst, Australia) mouse
genotyping service. Mice were then processed at the University of Wollongong.
Brilliant Blue G injections
BBG was diluted at 6 mg/mL in sterile 0.9% NaCl (saline). Both saline and the BBG prepa-
ration were filter-sterilised through 0.22 µm filters (Merck Millipore) and stored at−20 ◦C
until required. Mice were injected intraperitoneally (i.p.) three times per week with BBG
(45.5 mg/kg) from 62–64 d (i.e., prior to clinical disease onset) until end-stage, using Ultra-
Fine 0.5 mL, 29G syringes (BD Biosciences, San Diego, CA, USA). Control littermates were
injected i.p. with an equivalent volume of saline. Injections were performed on alternating
sides of the abdomen to minimise irritation.
Body weight measurements
Body weight was assessed three times a week prior to each injection using a Classic
Plus PB602-S/M-FACT balance (Mettler Toledo, Columbus, OH, USA), with two initial
measurements taken before the first injection, the average of which were defined as the
pre-symptomatic diseasemaximumbodyweight (i.e., beginning at 58–60 d).Measurements
were taken at the same time of day to minimise changes due to diurnal variations.
ALS score
Mice were scored three times a week prior to each injection to assess neurological deficit,
using the criteria outlined by the ALS Therapy Development Institute (Table 3). Scoring
started at 58–60 d, with each score taken at the same time of day.
Rotarod performance
Motor coordination was assessed weekly, beginning the first week of treatment (58–63 d),
using a five-lane accelerating rotarod (RotaRod Advanced, TSE Systems, Hesse, Germany).
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Table 3 Neurological scoring system.
Score Criteria
0 Full extension of hind legs away from lateral midline when mouse is suspended by its tail;
mouse can hold this for 2 s, suspended 2–3 times
1 Collapse or partial collapse of leg extension towards lateral midline (weakness) or trembling of
hind legs during tail suspension
2 Toes curl under at least twice during walking of 12 inches, or any part of foot is dragging along
cage bottom/table
3 Rigid paralysis or minimal joint movement, foot not being used for generating forward motion
4 Mouse cannot right itself within 30 s after being placed on either side
Mice received two training sessions in the week prior to recording. These sessions consisted
of one acclimatisation run with the rod rotating at a constant speed of 10 revolutions per
minute (rpm), followed by two to three runs with the rod accelerating from 4–20 rpm
over 180 s. Short rest intervals (minimum of 30 s) were given between runs. For testing,
the rod was programmed to rotate at a constant speed of 4 rpm for 5 s to allow mice to
acclimatise, followed by acceleration from 4–20 rpm over 180 s. The length of time mice
could remain on the rod was recorded as the latency to fall, registered automatically by
light-beam sensors under the rod. Mice were given at least three runs, with a minimum of
30 s between runs, to obtain 3 readings of at least 5 s. The maximum time each animal was
able to remain on the rod each week was recorded and included in the data analysis. Mice
that were unable to grip the rod due to advanced disease were given a minimum latency to
fall of 5 s, the baseline time.
Survival and end-stage
Transgenic SOD1G93A mice suffer from paralysis and muscle atrophy as disease progresses
(Gurney et al., 1994). Thus, to minimise suffering, the disease end-stage was defined when
mice first showed either (1) a 15% loss in body weight compared to their initial pre-
symptomatic disease maximum body weight or (2) an inability to right themselves within
30 s after being placed on either side (i.e., a score of 4). Once the end-stage had been reached,
mice were euthanised by asphyxiation using a slow-fill carbon dioxide inhalation technique.
Deceased animals with matching littermate controls were split into three post-study
groups. For the first two groups, deceased mice were perfused with phosphate-buffered
saline (PBS) followed by 4% PFA, or with PBS alone, and brains and spinal cords collected
for immunohistochemical and biochemical analyses, respectively. For the third group,
serum, spleens and livers were collected from non-perfused animals for further analysis.
Immunohistochemistry
Spinal cord processing
Immediately following euthanasia, mice were transcardially perfused with PBS followed by
4% PFA once perfusate ran clear. Spinal cords were then dissected, post-fixed with 4% PFA
at RT for 2 h, and then washed twice with PBS. Following this, spinal cords were cryopro-
tected in 30% sucrose in PBS at 4 ◦C for a minimum of 2 d. Tissue was embedded in OCT
medium, frozen by suspending above a layer of liquid nitrogen, and stored at −80 ◦C
(maximum of 10 d). Spinal cord transverse sections of 20 µm thickness were cut from the
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lumbar regions of the spinal cords on a CM1950 cryostat (Leica, Mannheim, Germany),
using spinal cord enlargement to identify the lumbar region. Sections were mounted onto
StarFrost R© advanced adhesive slides (Knittel Glaser, Braunschweig, Germany) and stored
at −80 ◦C (maximum of four weeks).
Iba1 and β3-tubulin staining
Microglia and motor neuron numbers were assessed by staining mounted spinal cords for
Iba1 and β3-tubulin, respectively. Firstly, a pap pen (Daido Sangyo, Tokyo, Japan) was used
to separate tissue sections on the same slide. All incubations were carried out in a humidified
chamber. Sections were fixed with 4% PFA in PBS at room temperature (RT) for 15 min,
and then washed three times with PBS over 30 min. Sections were then blocked with 20%
NHS in PBS at RT for 20 min, and incubated at 4 ◦C overnight with rabbit anti-Iba1 poly-
clonal antibody (pAb) (0.1µg/100µL) andmouse β3-tubulinmonoclonal antibody (mAb)
(0.5 µg/100 µL), or rabbit IgG isotype control pAb and mouse IgG2a isotype control at
corresponding concentrations, all in PBS containing 1% BSA, 0.2% NHS and 0.05%NaN3.
The following day, sections were washed as above, and incubated at RT for 1 h with
Alexa Fluor 647-conjugated goat anti-rabbit IgG Ab (0.3 µg/100 µL) and Alexa Fluor 488-
conjugated goat anti-mouse IgG Ab (0.3 µg/100 µL) in PBS containing 0.2% NHS. Cells
were washed as above and then coverslipsmounted onto tissue sections with 50% (v/v) glyc-
erol gelatin in PBS. Coverslips were sealed with nail varnish. Sections were visualised using
a TCS SP5 II confocal imaging system and images of anterior horns captured using Leica Ap-
plication Suite Advanced Fluorescence Lite software (version 2.6.3) (Leica) (excitation 633,
emission collected at 655–695 nm for Iba1; excitation 488 nm, emission collected at 510–550
nm for β3-tubulin). Images were taken of 6–12 anterior horns per animal, for a total of 12
animals (6 per treatment group). Spinal cord anterior horns were defined as the regions
of gray matter on the ventral side of a horizontal line crossing through the central canal.
Motor neuron counts
The numbers of motor neurons in anterior horns were manually counted using images of
β3-tubulin-stained spinal cords visualised in Leica Application Suite Advanced Fluores-
cence Lite software. Motor neurons were defined as cells with cell body diameters of at least
15 µm showing positive immunostaining for β3 tubulin. Counts from the right and left
anterior horns for each section were averaged, and then the average count from 3–6 sections
used as a single measurement per animal for statistical analyses.
Microglia density
Microglia density was assessed in anterior horns using images of Iba1-stained spinal cords
and ImageJ software (version 1.48) (National Institutes of Health, Bethesda, MD). Firstly,
thresholds were adjusted into 16-bit black and white images to account for any differences
in the intensity of staining or in the background fluorescence between sections. Particles
between 10–1,000 pixel units were then counted, and the percent area showing positive
immunostaining for Iba1 of the total anterior horn calculated. Percent areas from the right
and left anterior horns for each section were averaged, and then the average count from
3–6 sections used as a single measurement per animal for statistical analyses.
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Immunoblotting
Spinal cord protein extraction
Immediately following euthanasia, mice were transcardially perfusedwith PBS. Spinal cords
were then dissected, and the lumbar portion excised using spinal cord enlargement to iden-
tify the region. Lumbar spinal cord segments were snap-frozen in liquid nitrogen and stored
at −80 ◦C until required. Detergent-soluble proteins were extracted from lumbar spinal
cords by homogenising tissue in ice-cold neuronal protein extraction reagent containing 100
×HaltTM protease inhibitor cocktail using amicropestle. A ratio of 10µL extraction reagent
per 1 mg of tissue was utilised. Homogenates were incubated on ice for 10 min and cleared
(20,000× g at 4 ◦C for 10 min). To extract detergent-insoluble proteins, the resulting pellet
was resuspended in 0.5 M Tris HCl (pH 6.8) containing 2% w/v SDS at the same volume
as utilised for soluble protein extraction (to maintain a consistent concentration with the
original solution), and incubated at RT for 10 min. Unsolubilised material was cleared
(20,000 × g for 15 min). Soluble and insoluble protein samples were stored at −20 ◦C.
P2X7 and SOD1 protein detection
Soluble protein (50 µg) or an equivalent volume of insoluble protein were separated under
reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN TGX Stain-
Free Gels (Bio-Rad, Hercules, CA, USA). Before immunoblotting, equal protein loading
was confirmed by visualising stain-free gels using a Bio-Rad Criterion Stain Free Imager and
Image Lab software. Proteins were then transferred to nitrocellulose membranes (Bio-Rad)
using a Bio-Rad Trans-Blot Turbo Transfer System. To allow for separate P2X7 and SOD1
immunoblotting, membranes were cut horizontally between 25 and 37 kDa, using the pre-
stained marker as a guide. Both halves were then blocked at RT for 1 h with Tris-buffered
saline (250 mM NaCl and 50 mM Tris, pH 7.5) containing 0.2% Tween-20 and 5% milk
powder, and then incubated at 4 ◦C overnight with either an anti-P2X7 pAb (1:500) or anti-
SOD1pAb (1:1000) inTris-buffered saline containing 0.2%Tween-20 and 5%milk powder.
Membranes were washed three times over 30 min with Tris-buffered saline containing
0.2% Tween-20. Membranes were then incubated at RT for 1 h with peroxidise-conjugated
anti-rabbit (1:1000) or anti-sheep (1:500) IgG Ab (for P2X7 or SOD1, respectively) in
Tris-buffered saline containing 0.2% Tween-20 and 5% milk powder. Membranes were
washed as above, and proteins visualised using chemiluminescent substrate and Amersham
Hyperfilm ECL (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Films were
processed using GBX Developer and Replenisher, and GBX Fixer and Replenisher as per
the manufacturer’s instructions (Kodak Australasia, Collingwood, Australia). Images of
films were collected using a GS-800 Calibrated Densitometer (Bio-Rad). Relative P2X7
and SOD1 was quantified from these images using ImageJ software, normalising to a single
soluble protein sample included on all gels.
Serum monocyte chemoattractant protein-1 measurements
Blood was collected immediately following euthanasia via cardiac puncture using a 27G
PrecisionGlide needle (BD Biosciences). Blood was incubated at RT for 45–90 min and
then centrifuged (1,700× g for 5min). Serumwas stored at−80 ◦C. The amount ofMCP-1
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present in serum was measured using a mouse CCL2 (MCP-1) ELISA Ready-SET-Go! kit
(eBioscience, San Diego, CA, USA), as per the manufacturer’s instructions.
Splenic leukocyte phenotyping
Spleens from euthanisedmice were homogenised in PBS and filtered through Falcon 70µm
nylon filters (BDBiosciences). Cells were washedwith PBS (300× g for 5min), resuspended
in lysing buffer (155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM Na2EDTA, pH 7.4), and
incubated at RT for 5 min. Cells were then washed as above and resuspended in cold PBS
containing 2%FBS.Cells (1×106/tube)were incubated on ice for 20minwith combinations
of fluorochrome-conjugated anti-mouse mAbs or corresponding isotype control mAbs.
Cells were washed as above, and events collected using a LSRFortessa X-20 Cell Analyzer
(BD Biosciences) (excitation 488 nm, emission collected with 525/50 and 695/40 band-pass
filters for FITC- and PerCP/Cy5.5-conjugated mAbs, respectively; excitation 561, emission
collected with 585/15 band-pass filter for PE-conjugated mAbs; excitation 640, emission
collected with 670/30 band-pass filter for APC-conjugated mAbs). Percentages of leukocyte
subsets were determined using FlowJo software (version 8.7) (Tree Star, Ashland,OR,USA).
P2X7 expression by qPCR
Sections of livers and spleens, approximately 5 mm3 in size, were stored in RNAlater
at 4 ◦C. After 1–2 d, tissues were transferred to −20 ◦C. Tissues were removed from
RNAlater and total RNA isolated using TRIzol reagent (ThermoFisher Scientific), as per the
manufacturer’s instructions. cDNAwas synthesised from isolated RNAusing qScript cDNA
Synthesis Kit (Quanta Biosciences, Gaithersburg, MD, USA), as per the manufacturer’s in-
structions. qPCR amplification was performed in a 10 µL reaction volume, containing 5 µL
2×TaqManUniversalMasterMix II (ThermoFisher Scientific), 2µL liver or spleen cDNA,
0.5 µL of 20 × TaqMan Gene Expression Assay-Specific primers/probes (ThermoFisher
Scientific), and PCR-grade water. Standard primers for murine P2RX7 (FAM-labelled;
Mm00440578_m1) and murine glyceraldehyde 3-phosphate dehydrogenase (GAPDH )
(VIC-labelled; Mm99999915_g1) were used. Amplification was performed using an Eco
Real-Time PCR System (Illumina, San Diego, CA, USA). Reactions were held at 50 ◦C for 2
min and 95 ◦C for 10min, followed by 40 two-segment cycles of 95 ◦C for 15 s and 60 ◦C for
1min. A single fluorescence acquisition was taken each cycle, using FAM (505–545 nm) and
VIC (562–596 nm) filter combinations. No-template controls were included in each run
and all samples were run in triplicate. cDNA obtained from the spleen of a BALB/c mouse
(Watson et al., 2014) was also included in each run to compare relative P2X7 expression
(given a value of 1). Relative gene expression was normalised to the murine GAPDH
housekeeping gene and determined using EcoStudy software (version 4.1.2.0) (Illumina).
Data presentation and statistical analyses
Data is presented as mean ± SD, unless otherwise indicated. Differences between multiple
treatments were compared by ANOVA paired with Tukey’s HSD post-tests. For single
comparisons, unpaired Student’s t -tests were performed. Differences in body weight
between treatment groups were compared using an unpaired Student’s t -tests in two ways:
first, for the mean percentage body weight for each mouse over the entire period of the
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study; second, for the percentage body weight for each mouse at each recorded time-point.
For ALS score, rotarod performance and survival data, differences in the values of BBG-
and saline-treated mice were assessed using Kaplan–Meier analysis paired with log-rank
tests, considering the time to reach a consistent score of 2, drop to a consistent run of less
than 60 s or end-stage, respectively, as an event. To prevent decomposition of means due to
animals reaching end-stage, for weight, score and rotarod analyses, the last values prior to
euthanasia were carried forward until the last mouse in each group had reached end-stage.
These values were used to compute means at the end of the study. The software package
Prism 5 for Windows (version 5.01) (GraphPad Software, San Diego, CA, USA) was used
for all statistical analyses, with differences considered significant for P < 0.05.
RESULTS
Brilliant Blue G treatment reduces body weight loss in SOD1G93A mice,
but has no effect on clinical score, motor coordination or survival
The P2X7 antagonist, BBG, has been used in over 20 pre-clinical studies of neurological-
related disease in rodents (Bartlett, Stokes & Sluyter, 2014). To investigate the therapeutic
efficacy of BBG treatment on ALS progression, SOD1G93A mice were treated with saline or
BBG from 62–64 d (i.e., prior to clinical disease onset) until end-stage, and body weight,
ALS score and motor coordination recorded for the duration of the study.
Body weight of saline- and BBG-treated SOD1G93A mice was maintained or increased
until approximately 105 d, after which continuous body weight loss was observed (Fig.
1A). Overall, BBG-treated mice had greater initial weight gain and a delayed decline in
weight compared to saline-treated mice, in addition, BBG treated mice had a higher mean
percentage body weight (P = 0.014, n= 21), when calculated for eachmouse over the entire
period of the study (Fig. 1A, insert). Furthermore, at 63, 66, 80, 82, 84, 87, 89, 91, 94, 96,
98, 101, 103, 105, 108, 117, 119, 122 and 131 d, BBG-treated mice had significantly greater
percentage body weights compared to saline-treated mice (P < 0.05, n= 21) (Fig. 1A).
To assess neurological deficit, mice were scored from 58-60 d using the criteria outlined
by the ALS Therapy Development Institute (Table 3). At 58–60 d, all saline- and BBG-
treated mice had clinical scores of 0 (Fig. 1B). These scores increased throughout the study,
plateauing at an approximate score of 2.5 at 145 and 150 d for saline- and BBG-treatedmice,
respectively. Overall, considering the time to maintain a consistent score of 2 as an
event, there was no significant difference in score between saline- and BBG-treated mice
(P = 0.349, n= 21) (Fig. 1B).
Motor coordination was assessed weekly using an accelerating rotarod, beginning at
58–63 d.Motor coordination initially rose for both saline- andBBG-treatedmice, consistent
withmice continuing to learn how to use the rod, andwas thenmaintainedwith some varia-
tion until 95 d (Fig. 1C). After 95 d, motor coordination rapidly declined for both treatment
groups, with comparable rates of decline (P = 0.311, n= 21 considering the time to reach
a latency to fall consistently less than 60 s) (Fig. 1C).
End-stage was considered reached once mice displayed either a 15% loss in body weight
compared to their initial pre-symptomatic disease maximum body weight, or an inability
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Figure 1 Brilliant Blue G (BBG) treatment reduces body weight loss in SOD1G93A mice. SOD1G93A
mice were injected i.p. with 45.5 mg/kg BBG or an equivalent volume of saline 3 times per week from 62–
64 d until end-stage. During this period, (A) body weight, inset shows the mean body weight over the en-
tire experiment, (B) neurological deficit and (C) motor coordination were assessed (A–B) three times or
(C) once per week using (B) the ALS score criteria outlined by the ALS Therapy Development Institute or
(C) an accelerating rotarod programmed to rotate at a constant acclimatising speed of 4 rpm for 5 seconds
(s), followed by acceleration from 4–20 rpm over 180 s. (D) Mice were euthanased once either a 15% loss
in body weight compared to initial pre-symptomatic disease maximum body weight was reached or an
inability to right within 30 s after being placed on either side was demonstrated. Results are shown as the
(A–C) mean (A) percentages of the pre-disease (asymptomatic) maximum body weight, (B) ALS score or
(C) latency to fall (A–C)±SD or (D) percent survival for BBG- and saline-treated mice. Comparisons be-
tween saline- and BBG-treated mice were made using (A) an unpaired Student’s t -test on average weight
of mice over the entire period or (B–D) log-rank tests.
to right themselves within 30 s after being placed on either side (i.e., a score of 4). BBG
treatment, beginning at 62–64 d, did not affect the survival rate of SOD1G93A mice (saline
141 ± 6 d vs. BBG 144 ± 6 d, P = 0.270, n= 21), with similar rates of decline in percent
survival observed for both saline- and BBG-treatedmice (Fig. 1D).However, there appeared
to be a tendency for this rapid decline to be delayed in BBG-treated mice (Fig. 1D).
Brilliant Blue G treatment reduces body weight loss and prolongs
survival in female but not male SOD1G93A mice, but has no effect on
clinical score or motor coordination in either sex
The effects of P2X7 antagonism in a mouse model of ALS have previously been reported
to be gender-dependent (Cervetto et al., 2013). Thus, subgroup analyses by gender were
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performed to elucidate whether any differences in body weight, clinical score, motor coor-
dination or survival could be observed following BBG treatment in either males or females.
Body weight loss occurred in a comparable manner for both saline- and BBG-treated
male mice (P = 0.649, n= 8–9) (Fig. 2A and insert). Furthermore, there were no significant
differences in male body weight as a percentage of the pre-symptomatic disease maximums
on any weight measurement day. In contrast, BBG-treated female mice had significantly
greater initial weight gain and a delayed decline in weight compared to saline-treated female
mice over the entire period of the study (P = 0.006, n= 12–13) (Fig. 2A and insert). At 63,
66, 73, 80, 82, 84, 87, 89, 91, 94, 96, 98, 101, 103, 105, 108, 117, 119, 122, 126 and 131 d,
BBG-treated female mice had significantly greater percentage body weights compared to
saline-treated female mice (P < 0.05, n= 12–13) (Fig. 2A).
Score trajectories similar to those described above were observed for both male and
female saline- and BBG-treatedmice (Fig. 2B). Overall, there were no significant differences
in score between saline- and BBG-treated male or saline- and BBG-treated female mice
when considering the time to maintain a consistent score of 2 as an event (male P = 0.647,
n= 8–9; female P = 0.084, n= 12–13) (Fig. 2B).
Similar patterns ofmotor deficit to that described above were also observed for bothmale
and female saline- and BBG-treated mice (Fig. 2C), again with comparable rates of decline
between those treated with saline and those with BBG (male P = 0.390, n= 8–9; female P =
0.586, n= 12–13; considering the time to reach a latency to fall consistently less than 60 s).
When considering males alone, survival was not affected by BBG treatment (saline 143
± 7 d vs. BBG 142 ± 6 d, P = 0.582, n= 8–9) (Fig. 2D). Conversely, for females, BBG
treatment extended survival (saline 139± 6 d vs. BBG 145± 6 d, P = 0.035, n= 12–13) (Fig.
2D). Whilst similar rates of decline were observed for both female saline- and BBG-treated
mice, this decline was delayed following BBG treatment in females.
Brilliant Blue G treatment does not reduce motor neuron loss or
microgliosis in SOD1G93A mice
To determine the effect of BBG-treatment on motor neuron loss and microgliosis, neurons
and microglia in the anterior horn of lumber spinal cords from end-stage saline- and
BBG-treated mice were labelled and imaged by confocal microscopy. Motor neurons were
counted and the density of microglia assessed. The lumbar spinal cord was chosen as this is
the CNS tissue in which lower motor neurons reside and that is predominately damaged
during ALS (Apolloni et al., 2013a).
Representative images of stained anterior horn sections from saline and BBG-treated
SOD1G93A mice are shown (Fig. 3). A stained section derived from a WT littermate of
corresponding age is included for comparison. The average number of motor neurons,
identified as cells with cell body diameters of at least 15 µm, was similar between saline- and
BBG-treated SOD1G93A mice (saline 19.3 ± 2.0 vs. 19.5 ± 1.4 motor neurons, P = 0.868,
n= 6) (Fig. 3A). Similarly, there was no difference in the amount of microgliosis between
saline- and BBG-treatedmice (saline 2.6± 0.3% vs. 2.5± 0.8%, P = 0.821, n= 6) (Fig. 3B).
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Figure 2 Brilliant Blue G (BBG) treatment reduces body weight loss and prolongs survival in female,
but not male, SOD1G93A mice. SOD1G93A mice from Fig. 1 were stratified according to sex. Results are
shown as the (A–C) mean (A) percentages of the pre-disease (asymptomatic) maximum body weight,
inset shows the mean body weight over the entire experiment, (B) ALS score or (C) latency to fall (A–
C)±SD or (D) percent survival for male or female BBG- and saline-treated mice. Comparisons between
saline- and BBG-treated mice were made using (A) unpaired Student’s t -tests over the entire period or
(B–D) log-rank tests.
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Figure 3 Brilliant Blue G (BBG) treatment does not reduce motor neuron loss or microgliosis in the
anterior horn of SOD1G93A mice. Lumbar spinal cord transverse cross sections (20 µm) from BBG- or
saline-treated SOD1G93A mice at end-stage were fixed with paraformaldehyde and labelled with an (A)
anti-β3-tubulin mAb and Alexa Fluor 488-conjugated anti-IgG Ab or (B) anti-Iba1 pAb and Alexa Fluor
647-conjugated anti-IgG Ab, and (A, B) analysed by confocal microscopy. Representative confocal im-
ages of anterior horn are shown. Bars represent 100 µm. A stained section derived from a single wild type
(WT) littermate of corresponding age is shown for comparison. Results shown as mean (A) motor neuron
(neuron ≥ 15 µm in diameter) count per anterior horn or (B) percent area positive for Iba-1 (A, B)±SD,
n= 6 SOD1G93A mice (male and female). Symbols represent individual animals.
Brilliant Blue G treatment does not affect the amount of detergent-
soluble or -insoluble lumbar SOD1 or P2X7 protein in SOD1G93A mice
To determine whether prolonged BBG treatment reduced the amount of P2X7 and SOD1
in the lumbar spinal cords of end-stage SOD1G93A mice, detergent-soluble and -insoluble
lumbar spinal cord protein fractions were examined by immunoblotting and densitometry.
All samples were normalised to one soluble sample (indicated in red). Monomeric SOD1
(16 kDa) was present in both soluble and insoluble fractions, with similar amounts detected
between saline- andBBG-treatedmice (solubleP = 0.842, n= 7; insolubleP = 0.149, n= 7)
(Figs. 4A and 4C).
Immunoblotting with a P2X7 pAb raised against an extracellular epitope revealed multi-
ple proteins, with approximate sizes of 155, 60 and 50 kDa, as well as a doublet around 73–89
kDa (Figs. 4B and 4D). This doublet most likely corresponds to full-length P2X7monomers
(P2X7A) (Masin et al., 2012). There was no difference in total P2X7 amounts between
saline- and BBG-treated mice in either soluble or insoluble fractions (soluble P = 0.821,
n= 7; insoluble P = 0.776, n= 7) (Figs. 4B and 4D). There was also no difference in
amounts of P2X7A between saline- and BBG-treated mice in either soluble or insoluble
fractions (soluble P = 0.571, n= 7; insoluble P = 0.689, n= 7) (Figs. 4B and 4D).
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Figure 4 Brilliant Blue G (BBG) treatment does not affect the amount of detergent-soluble or
-insoluble lumbar SOD1 or P2X7 protein in SOD1G93A mice. (A, B) Soluble or (C, D) insoluble protein
fractions from homogenised BBG- or saline-treated SOD1G93A mouse lumbar spinal cords at end-stage
were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and
incubated with (A, C) anti-SOD1 or (B, D) anti-P2X7 pAbs. Representative blots are indicated. Results
shown as mean (A, B) soluble or (C, D) insoluble SOD1 or P2X7 protein± SD, n = 7 mice (male and
female). Amounts shown are relative to corresponding soluble proteins of one saline mouse (indicated in
red). Symbols represent individual animals.
Brilliant Blue G treatment partially increases serum MCP-1
concentrations in SOD1G93A mice
MCP-1, an inflammatory chemokine involved in the recruitment ofmonocyte-derived cells
such as microglia, is up-regulated in ALS mice (Kawaguchi-Niida et al., 2013) and patients
(Henkel et al., 2004; Nagata et al., 2007; Wilms et al., 2003). Thus, the concentrations of
MCP-1 in the serum of end-stage saline- and BBG-treated mice was investigated to
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Figure 5 Brilliant Blue G (BBG) treatment partially increases serummonocyte chemoattractant
protein-1 (MCP-1) concentrations in SOD1G93A mice. Serum from BBG- or saline-treated SOD1G93A
mice at end-stage was collected and MCP-1 concentrations determined using an ELISA. Results shown as
means± SD, n= 6 (male and female). Symbols represent individual animals.
determine whether BBG treatment was able to reduce serum MCP-1. Low concentrations
ofMCP-1 were detected in both saline- and BBG-treatedmice (Fig. 5). In contrast to expec-
tations, serumMCP-1 concentrations were 1.4-fold higher in BBG-treated mice compared
to saline-treated mice; a difference approaching statistical significance (P = 0.052, n= 6).
Brilliant Blue G treatment does not affect the distribution of splenic
leukocytes from SOD1G93A mice
The percentage of splenic leukocyte subsets of total CD45+ leukocytes from end-stage
saline- and BBG-treated SOD1G93A mice was investigated by flow cytometry. There were
no differences in the percentages of B cells (CD19+CD3−; P = 0.362, n= 6), total T cells
(CD3+CD19−; P = 0.615, n= 6), CD8+ T cells (CD8+CD3+CD19−; P = 0.643, n= 6),
CD4+ T cells (CD4+CD3+; P = 0.549, n= 6), regulatory T cells (CD25+CD4+CD3+;
P = 0.239, n= 6), dendritic cells (DCs; CD11b±CD11c+; P = 0.981, n= 6), macrophages
(MOs; CD11b+CD11c− Ly6G−; P = 0.130 n= 6) or polymorphonuclear neutrophils
(PMNs; CD11b+CD11c− Ly6G+; P = 0.084, n= 6) between saline- and BBG-treated mice
(Fig. 6).
Brilliant Blue G treatment does not affect P2X7 expression in the
spleens or livers of SOD1G93A mice
To determine if the prolonged BBG treatment altered P2X7 expression in non-CNS tissues,
the murine P2X7 expression, normalised to murine GAPDH, in spleens and livers from
end-stage saline- and BBG-treatedmice was determined by qPCR. Relative P2X7 expression
in either the spleens (P = 0.644, n= 6) or livers (P = 0.942, n= 6) was similar between
saline- and BBG-treated mice (Fig. 7).
The amount of detergent-soluble or -insoluble lumbar SOD1 or P2X7
protein does not change over time in female SOD1G93A mice
To determine whether the amount of SOD1 or P2X7 protein in the lumbar spinal cords
of SOD1G93A mice change with age, and whether differences exist in P2X7 protein levels
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Figure 6 Brilliant Blue G (BBG) treatment does not affect the distribution of splenic leukocytes from
SOD1G93A mice. Splenic leukocytes from BBG- or saline-treated SOD1G93A mice at end-stage were la-
belled with fluorochrome-conjugated mAbs. The percentage of (A) B cells (CD19+CD3−), (B) T cells
(CD3+CD19−), (C) CD8+ T cells (CD8+CD3+CD19−), (D) CD4+ T cells (CD4+CD3+), (E) regulatory
T (Treg) cells (CD25+CD4+CD3+), (F) dendritic cells (DCs; CD11b±CD11c+), (G) macrophages (MOs;
CD11b+CD11c−Ly6G−) and (H) polymorphonuclear neutrophils (PMNs; CD11b+CD11c−Ly6G+) of the
total CD45+ leukocyte population were determined by flow cytometry. Results shown as means± SD, n=
6 (male and female). Symbols represent individual animals.
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Figure 7 Brilliant Blue G (BBG) treatment does not affect P2X7 expression in the spleens or livers of
SOD1G93A mice. RNA was isolated from (A) spleens and (B) livers from BBG- or saline-treated SOD1G93A
mice at end-stage. cDNA was synthesised from isolated RNA and amplified by qPCR using probes for
P2X7 and GAPDH to determine P2X7 expression (normalised to GAPDH). P2X7 expression is relative to
one control sample (obtained from BALB/c spleen). Results shown as means± SD, n = 6 (male and fe-
male). Symbols represent individual animals.
between SOD1G93A mice and their WT littermates lacking the SOD1 transgene, detergent-
soluble and -insoluble lumbar spinal cord fractions were prepared and proteins examined
by immunoblotting. Given that BBG treatment delayed weight loss and prolonged survival
in females, but not males (Fig. 2), female mice were used for these analyses. Human SOD1
(16 kDa) was present in both soluble and insoluble fractions derived from SOD1G93A mice,
but was not detected in fractions derived fromWT non-transgenic littermates (Figs. 8A and
8B). The amount of detergent-soluble and -insoluble SOD1 did not significantly change
over time in lumbar spinal cords of SOD1G93A mice (soluble P = 0.160, n= 4–5; insoluble
P = 0.794, n= 4–5).
Similar to previous observations (Fig. 4), immunoblotting with a P2X7 Ab raised against
an extracellular epitope revealed multiple proteins, with approximate sizes of 160, 60 and
50 kDa, as well as a doublet around 80–90 kDa (Figs. 8C and 8D). Total P2X7 amounts
were similar between fractions derived from WT and SOD1G93A mice at each time point.
The amount of detergent-soluble or -insoluble total P2X7 did not significantly change
over time in lumbar spinal cords of WT or SOD1G93A mice (SOD1 soluble P = 0.144,
n= 4–5; WT soluble P = 0.292, n= 3–4; SOD1 insoluble P = 0.869, n= 4–5; WT insoluble
P = 0.445, n= 3–4) (Figs. 8C and 8D). Similarly, there were no differences in amounts of
lumbar P2X7A between WT and SOD1G93A mice at each time point for either fraction,
and no significant differences in the amount of lumbar P2X7A over time for SOD1G93A
mice (soluble P = 0.170, n= 4–5; insoluble P = 0.115, n= 4–5). Conversely, WT mice at
60 and 90 d had significantly less detergent-soluble lumbar P2X7A than at 30 d (P = 0.007,
n= 3–4), and at 90 and 120 d had significantly more detergent-insoluble lumbar P2X7A
than at 30 d (P = 0.027, n= 3–4) (Figs. 8C and 8D).
DISCUSSION
In the current study, BBG treatment beginning at pre-onset of clinical ALS (62–64 d)
delayed weight loss and prolonged survival in female, but not male, SOD1G93A mice.
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Figure 8 The amount of detergent-soluble or -insoluble lumbar SOD1 or P2X7 protein does not
change over time in female SOD1G93A mice. (A, C) Soluble or (B, D) insoluble protein fractions from
homogenised female wild type (WT) or SOD1G93A mouse lumbar spinal cords at different ages were
separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and
incubated with (A, B) anti-SOD1 or (C, D) anti-P2X7 pAbs. Representative blots are indicated. Results
shown as mean (A, C) soluble or (B, D) insoluble SOD1 or P2X7±SD, n= 3–5 mice; *P < 0.05 compared
to corresponding 30 d. Amounts shown are relative to corresponding soluble proteins of one WT mouse
at 30 days of age (indicated in red). Symbols represent individual animals.
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Treatment had no effect on ALS score or motor coordination in either sex. Furthermore,
BBG treatment had no effect on motor neuron loss, microgliosis, lumbar SOD1 or P2X7
protein amounts, splenic leukocyte immunophenotype, or P2X7 expression in the spleen
or liver at end-stage. BBG treatment partially, but not significantly, increased serum
MCP-1. Together, this suggests a limited efficacy of BBG on ALS progression as used in the
current study. Furthermore, there was no difference in the amount of lumbar P2X7 protein
observed in SOD1G93A mice of different ages or between SOD1G93A andWTmice at any age.
The therapeutic effects of BBG in SOD1G93A murine models of ALS have been reported
in two other independent studies (Apolloni et al., 2014; Cervetto et al., 2013). In both these
studies, treatment with BBG delayed disease onset, improved motor coordination, disease
scores and motor neuron survival, and reduced weight loss and microgliosis. Comparisons
of these studies with the current study highlight important parameters effecting drug
efficacy in murine ALS models, which should be considered in future studies.
One important parameter is gender. In the current study, BBG treatment slowed weight
loss and extended survival in female, but notmale,mice. This is consistent with the extended
lifespan of female heterozygous and homozygous P2X7 knock-out (P2X7KO)/SOD1G93A
mice compared to P2X7WT/SOD1G93A mice (Apolloni et al., 2013a). Gender also affected
P2X7 antagonism in another study investigating BBG efficacy in the SOD1G93A murine
model of ALS. However, in contrast to the current study, BBG significantly delayed the
time taken for 10% weight loss and a decline in motor coordination to be observed in male,
but not female, mice (Cervetto et al., 2013). Furthermore, this gender dependency was not
observed for any other reported outcomes, including weight or motor coordination,
following BBG treatment in another previous study (Apolloni et al., 2013a). Gender-specific
outcomes may be impacted by differences in the genetic background of SOD1 mice
(Heiman-Patterson et al., 2005) or differences in sex hormones such as oestrogens (Choi et
al., 2008; Groeneveld et al., 2004; Trieu & Uckun, 1999).
Vehicle composition is another factor that may have influenced the efficacy of BBG
observed in the current study compared to previous studies. In the current study, dimethyl
sulfoxide (DMSO) was not included in the vehicle for BBG delivery, while DMSO was
present in the vehicle solution in both previous studies investigating the therapeutic effects
of BBG (Apolloni et al., 2014; Cervetto et al., 2013). In the current study, DMSO was ex-
cluded as BBGwas soluble in its absence and given that it is well known to be toxic, especially
when used chronically or at concentrations greater than 10% (Kloverpris et al., 2010). Due
to the fact that intraperitoneally delivered DMSO is able to cross the blood–brain barrier
(Broadwell, Salcman & Kaplan, 1982), it is possible that the lack of DMSO in the current
study prevented adequate BBG blood–brain barrier penetrance. In a study of spinal cord
injury, intravenous administration of a similar concentration of BBG in the absence of
DMSO resulted in blue colouring in the injury area, but not surrounding tissue (Peng et
al., 2009). This suggests that BBG entered the site of injury mainly via the disrupted spinal
blood–brain barrier in this study, and that DMSO may be required in the drug vehicle for
adequate BBG blood–brain barrier penetrance.
The limited efficacy of BBG in the current study may have been due to the dose used.
BBG was used at 45.5 mg/kg due to the efficacy of this dose in murine models of other
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neurodegenerative conditions, includingHuntington’s disease and spinal cord injury (Diaz-
Hernandez et al., 2009; Peng et al., 2009). This dose also improved disease outcomes in
C57BL/6J × SJL/J hybrid SOD1G93A mice (Cervetto et al., 2013). However, in the study
of Apolloni et al. (2014), 50 mg/kg BBG had no effect on disease outcomes in C57BL/6J
SOD1G93A mice. When the BBG dose was increased to 250 mg/kg in this study, improve-
ments in behavioural scores, motor performance and median disease onset were observed
(Apolloni et al., 2014). This may indicate that the BBG dose utilised in the current study
was insufficient to fully antagonise P2X7 in the CNS of C57BL/6J SOD1G93A mice.
An important consideration when testing therapeutic intervention in ALSmousemodels
is the timing of treatment commencement. In the current study, BBG treatment was started
before the onset of symptoms. In comparison, Cervetto et al. (2013) began treatment at
disease onset, with a similar BBG dosage, number of treatments per week and delivery
route utilised as in the current study. Thus, the differences observed between this and the
current study may be explained by the timing of treatment commencement. In the study by
Apolloni et al. (2014), BBG treatment was started at late pre-onset, resulting in a wide range
of beneficial effects on disease progression. Whilst this study only observed these effects
by utilising a five-fold higher dose of BBG than that used in the current study, these high
BBG doses were not effective when began during the asymptomatic or pre-onset phases
of disease. Collectively, this suggests a very tight window for therapeutic intervention
targeting P2X7. This is further supported by the exacerbated disease progression observed
in SOD1G93A mice lacking P2X7 (Apolloni et al., 2013a), and suggests that P2X7 may play
a dual role in ALS progression. In this regard, P2X7 activation may be neuroprotective in
the initial stages of disease, but neuroinflammatory or neurotoxic as the disease progresses.
This is consistent with the trophic and toxic actions mediated by P2X7 in surveilling and
activated microglia, respectively (Bartlett, Yerbury & Sluyter, 2013; Gendron et al., 2003;
Hide et al., 2000; Monif et al., 2009; Shieh et al., 2014).
Microgliosis and loss ofmotor neurons are twomajor hallmarks of disease in ALS.Whilst
these disease hallmarks were observed in the current study, there were no differences at end-
stage between untreated and BBG-treatedmice. In contrast, BBG treatment reduced lumbar
microglia activation and inflammatory microglial markers, enhanced neurotrophic factors
and improved motor neuron survival at end-stage in the study by Apolloni et al. (2014).
This is consistent with the anti-inflammatory effects resulting fromP2X7 inhibition in vitro,
whereby BBG treatment reduced the release of pro-inflammatory factors and subsequent
toxicity of SOD1G93A microglia towards neuronal cells (Apolloni et al., 2013b; D’Ambrosi
et al., 2009). In the current study, motor neuron and microglial numbers were assessed
without stratifying for gender due to the small n values of available samples. However, given
the limited clinical efficacy of BBG, increasing the n value to allow for gender stratification
may not be worthwhile. Furthermore, there is limited evidence that gender influences
motor neuron loss (Veldink et al., 2003).
An accumulation of SOD1-containing aggregates is another major hallmark of disease
in ALS. In the current study, detergent-insoluble SOD1 was present in lumbar spinal cords
of SOD1G93A mice at end-stage. However, there were no differences in the amounts of
detergent-insoluble SOD1 between saline- and BBG-treated SOD1G93A mice. Consistent
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with this data, ablation of P2X7 does not modify the lumbar SOD1 content in SOD1G93A
mice (Apolloni et al., 2013a). BBG, but not other P2X7 antagonists, prevents protease-
resistant prion protein accumulation in scrapie-infected microglial and neuronal cell lines,
and in the brains of prion-infected mice (Iwamaru et al., 2012). This suggests that BBG
has anti-aggregation properties, independent of its P2X7 interactions. However, given
the current data, the anti-aggregation properties of BBG may be restricted to anti-prion
activities, consistent with amolecular framework analogous to other anti-prion compounds
(Iwamaru et al., 2012).
P2X7 protein was detected in the lumbar spinal cord of SOD1G93A mice treated with
either saline or BBG. Similar amounts were detected between treatments, consistent with
the lack of effect of BBG on lumbar spinal P2X7 amounts in other studies (Apolloni et al.,
2014). In the current study, a number of bands were detected in addition to the expected
full length P2X7A isoform (73–89 kDa). These proteins were approximately 160, 80, 60 and
50 kDa in size, and may correspond to P2X7 dimers, non-glycosylated P2X7, P2X7 splice
variants or P2X7 breakdown products. C terminal truncated P2X7 variants have recently
been identified in mice (Masin et al., 2012). One of these, termed P2X713B, is detected in
the mouse CNS and has a molecular mass of approximately 60 kDa (Masin et al., 2012),
similar to one of the proteins detected in this current and other studies (Barth et al., 2007).
Interestingly, when expressed in human embryonic kidney (HEK)-293 cells, the majority of
P2X713B was retained in the endoplasmic reticulum and not efficiently trafficked to the cell
surface (Masin et al., 2012). Thismay explain differences in the amount of 60 kDa protein in
detergent-soluble and insoluble fractions in the current study.However, furtherworkwould
be required to identify whether this band does indeed correspond to a P2X7 splice variant.
In the current study, the amount of lumbar spinal cord P2X7 did not change significantly
with age in female SOD1G93A mice. It has been reported that there is no sexual dimorphism
in P2X7 expression at any age (Crain, Nikodemova & Watters, 2009). However, while
microglial P2X7 expression was maintained at similar levels from 21 to 365 d in healthy
C57BL/6mice in onemixed-sex study (Crain, Nikodemova & Watters, 2009), another found
that P2X7 protein increased with age in healthy Sprague–Dawley rats (Lai et al., 2013).
Furthermore, similar amounts of lumbar P2X7 protein were present in spinal cords from
WT and SOD1G93A mice at all investigated time points in the current study, while P2X7
immunoreactvities have been reported to be increased in spinal cords from (post-mortem)
humans with ALS and advanced-stage transgenic SOD1G93A rats (Casanovas et al., 2008;
Yiangou et al., 2006).
In the current study, P2X7 was detected in both detergent-soluble and -insoluble frac-
tions. The presence of detergent-insoluble P2X7 has been reported in mouse lung alveolar
epithelial cells, HEK-293 cells transfected with WT P2X7, mouse peritoneal macrophages
and rat submandibular glands (Barth et al., 2007;Garcia-Marcos et al., 2006;Gonnord et al.,
2009). In these studies, it was suggested that P2X7 partially localisedwith detergent-resistant
membranes, or lipid rafts, at the plasma membrane. This association was reported to be
dependent on the post-translational modification of P2X7 by palmitic acid (Gonnord
et al., 2009). In the current study, the amount of detergent-insoluble 75 kDa P2X7 was
relatively low, suggesting that the majority of 75 kDa P2X7 was localised in the plasma
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membrane. Determining whether the detergent-insoluble 75 kDa protein represented lipid
raft-associated or intracellular P2X7 was beyond the scope of the current work.
BBG treatment increased serum MCP-1 in SOD1G93A mice by 1.4-fold compared to
saline treatment; a difference that approached statistical significance (P = 0.052). MCP-1 is
up-regulated in ALS mice (Kawaguchi-Niida et al., 2013) and in patients with ALS (Henkel
et al., 2004; Nagata et al., 2007; Wilms et al., 2003), where it is thought to drive disease
progression. Whilst in vitro studies have showed that pre-incubation with BBG can reduce
P2X7-mediated accumulation of intracellular MCP-1 in rat microglia (Fang et al., 2011)
and prevent P2X7-mediated MCP-1 release from murine microglia (Shieh et al., 2014).
Thus, the current observation that serum MCP-1 was potentially increased in SOD1G93A
mice following BBG treatment was unexpected. Possible explanations for this finding is that
BBG treatment in vivo affects pathways other than the ATP-P2X7 signalling axis to promote
MCP-1 production or alters the circulatory system to extend the half-life of serumMCP-1.
CONCLUSIONS
In conclusion, BBG treatment reduced body weight loss and prolonged survival in female
SOD1G93A mice. This represents the first report of an extension in survival following P2X7
blockade in an ALS mouse model. Given that this result was seen only in females, the im-
portance of considering sex in pre-clinical studies is clear, consistent with reports by others
(Cervetto et al., 2013). Despite this, in the current study, BBG had no effect on body weight
loss or survival inmale SOD1G93Amice, or onALS score,motor coordination,motor neuron
loss, microgliosis, lumbar SOD1 or P2X7, serum MCP-1, splenic leukocyte immunophe-
notype or P2X7 expression at end-stage in either gender. While the other two studies
investigating the efficacy of BBG in ALS found more beneficial effects of this compound
at molecular and phenotypic levels, these effects did not correlate with an extension in
life span in these studies (Apolloni et al., 2014; Cervetto et al., 2013). Together, the different
outcomes obtained from these three studies highlight how drug regime may influence
disease outcomes in murine models of ALS.
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